Publications by authors named "Alan L Ho"

52Publications

Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.

Cancer 2020 Sep 18;126(17):3972-3981. Epub 2020 Jun 18.

Department of Hematology/Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.33036DOI Listing
September 2020

Sex disparities in salivary malignancies: Does female sex impact oncological outcome?

Oral Oncol 2019 07 22;94:86-92. Epub 2019 May 22.

Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2019.05.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559377PMC
July 2019

The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement.

Hum Pathol 2019 06 1;88:66-77. Epub 2019 Apr 1.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2019.03.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388159PMC
June 2019

Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.

Cancer Res 2018 08 14;78(16):4642-4657. Epub 2018 May 14.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-17-1925DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095730PMC
August 2018

Challenges and Opportunities for Developing New Therapeutics for Salivary Gland Cancers.

J Oncol Pract 2018 02;14(2):109-110

Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JOP.18.00039
Publisher Site
http://dx.doi.org/10.1200/JOP.18.00039DOI Listing
February 2018

OncoKB: A Precision Oncology Knowledge Base.

JCO Precis Oncol 2017 Jul 16;2017. Epub 2017 May 16.

, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , , Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Department of R&D and Bioinformatics, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
https://www.researchgate.net/profile/Debyani_Chakravarty/pub
Web Search
http://ascopubs.org/doi/10.1200/PO.17.00011
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586540PMC
http://dx.doi.org/10.1200/PO.17.00011DOI Listing
July 2017

Androgen Receptor Signaling in Salivary Gland Cancer.

Cancers (Basel) 2017 Feb 8;9(2). Epub 2017 Feb 8.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers9020017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332940PMC
February 2017

Unmet needs for patients with salivary gland cancer.

Oral Oncol 2016 09 1;60:142-5. Epub 2016 Jul 1.

Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2016.06.003DOI Listing
September 2016

Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.

J Nucl Med 2015 May 26;56(5):662-7. Epub 2015 Mar 26.

Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/content/early/2015/03/25/jnumed.1
Web Search
http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.114.150607
Publisher Site
http://dx.doi.org/10.2967/jnumed.114.150607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970467PMC
May 2015

Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy.

J Skin Cancer 2014 21;2014:284582. Epub 2014 Jul 21.

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 22, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/284582DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129159PMC
August 2014

Dermatofibrosarcoma protuberans, version 1.2014.

J Natl Compr Canc Netw 2014 Jun;12(6):863-8

From University of Michigan Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; City of Hope Comprehensive Cancer Center; University of Washington/Seattle Cancer Care Alliance; Huntsman Cancer Institute at the University of Utah; Roswell Park Cancer Institute; UC San Diego Moores Cancer Center; Moffitt Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Colorado Cancer Center; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; The University of Texas MD Anderson Cancer Center; Duke Cancer Institute; Fox Chase Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; University of Alabama at Birmingham Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Dana-Farber/Brigham and Women's Cancer Center; Vanderbilt-Ingram Cancer Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0081DOI Listing
June 2014

A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer.

Int J Radiat Oncol Biol Phys 2013 Nov;87(3):479-86

Department of Medicine, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2013.06.2043DOI Listing
November 2013

Moving toward a better understanding of radioiodine action.

Authors:
Alan L Ho

Endocrine 2013 Dec 30;44(3):553-4. Epub 2013 Aug 30.

Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-013-0024-xDOI Listing
December 2013

PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.

Anticancer Res 2013 Apr;33(4):1307-16

Jennifer Goodman Linn Laboratory of New Drug Development, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
April 2013

Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.

Mol Cancer Ther 2013 May 26;12(5):768-76. Epub 2013 Feb 26.

Laboratory of New Drug Development, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-1020DOI Listing
May 2013

The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.

Invest New Drugs 2013 Jun 24;31(3):787-97. Epub 2013 Jan 24.

Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228 160 E 53rd St., New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-9927-xDOI Listing
June 2013

Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

PLoS One 2012 10;7(7):e40439. Epub 2012 Jul 10.

Laboratory of New Drug Development, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040439PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393714PMC
March 2013

PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma.

Cancer Res 2012 Sep 10;72(17):4515-25. Epub 2012 Jul 10.

Laboratory of New Drug Development, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 300 East 66th Street, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-1319DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432680PMC
September 2012

The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.

Cell Cycle 2012 Feb 15;11(4):807-17. Epub 2012 Feb 15.

Laboratory of New Drug Development, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.11.4.19323DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318110PMC
February 2012

Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer.

Clin Adv Hematol Oncol 2011 Jan;9(1):32-41

Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
January 2011

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.

Lancet Oncol 2011 Aug 10;12(8):815-24. Epub 2010 Dec 10.

Ottawa Hospital Cancer Centre, Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(10)70245-XDOI Listing
August 2011